Temporomandibular Joint (TMJ) involvement in patients with ulcerative colitis (UC) is a rare manifestation. To the best of our knowledge there are only two cases in the literature reported the presence of TMJ involvement in a patient with UC. We report a case of 23-year-old female with a two-year history of UC she was complaining of unilateral temporomandibular jaw pain, the pain was severe enough to affect her daily activities, she was not able to speak and there was a limitation of mouth opening. The patient was only able to open her mouth for 2.5 cm. C-reactive protein and erythrocyte sedimentation rate were high, rheumatoid factor was negative. The computed tomography (CT) of the mandible and teeth reveals flattening with erosion of the condylar process of the left mandibular joint without the presence of joint effusion or soft tissue swelling. Our patient was managed by biological treatment Ustekinumab for 6 months, as a result the patient improved and she was able to open her mouth up to 4 cm. Clinicians should be aware of the importance of biological treatment in these circumstances, TMJ arthritis in UC patients is considered a rare and unusual picture of extraintesinal IBD manfistations.
Background/Objectives: The burden of ulcerative colitis (UC) is increasing in Saudi Arabia (KSA), and patients with UC often suffer from delays in diagnosis and appropriate management. This study investigates the current UC patient journey in KSA from the healthcare professionals’ (HCPs) perspective. It aims to evaluate treatment patterns, identify critical gaps, and provide insights to guide interventions that enhance the quality of life for UC patients in KSA. Methods: Quantitative interviews were conducted with 60 HCPs (45 gastroenterologists and 15 internal medicine specialists) from different regions in Saudi Arabia (KSA) using a Computer-Assisted Personal Interview (CAPI) system. The survey domains included clinical symptoms, diagnostic testing, endoscopic scoring, treatment goals, and medication sequencing. Results: Data were collected from 60 HCPs with an average of 17 ± 12.5 years of experience. Most patients with UC were referred by general practitioners (28%), internal medicine physicians (25%), followed by surgeons (16%). The first-ranked treatment goals were clinical remission (53.3%), endoscopic remission (35%), and improvement of quality of life (33.3%). For outpatient moderate-to-severe UC, the most common first-line treatments are oral systemic steroids (34%), 5-aminosalicylates (5-ASAs) (26%), and TNF-α inhibitors (21%). While second-line treatment rankings were TNF-α inhibitors (23%), followed by Interleukin 12/23 inhibitors (19%), and Janus kinase (JAK) inhibitors (14%). Sphingosine 1-phosphate (S1P) receptor modulators are not well-utilized due to a lack of availability (88%), unfamiliarity with the treatment (24%), and formulary exclusion (12%). Conclusions: In conclusion, most UC patients are referred by general practitioners. Treating gastroenterologists prioritize clinical remission as a treatment goal. Corticosteroids remain overutilized as reflected by treating physicians’ responses. The underutilization of advanced therapies underscores the need for enhanced education and improved access to integrate emerging therapies effectively.